![]() |
市场调查报告书
商品编码
1358975
到 2030 年医疗诊断中的人工智慧 (AI) 市场预测:按组件、领域、模式、AI 技术、用途、最终用户和地区进行的全球分析Artificial Intelligence in Medical Diagnostics Market Forecasts to 2030 - Global Analysis By Component, Specialty, Modality, AI Technology, Application, End User and By Geography |
根据 Stratistics MRC 预测,2023 年全球医疗诊断领域人工智慧 (AI) 市场规模将达到 13 亿美元,预计到 2030 年将达到 105 亿美元,预测期内年复合成长率为 34.2%。 。
医疗诊断中的人工智慧 (AI) 可以帮助医疗保健专业人员为患者做出准确、及时的治疗决策,从而有可能改善护理的可及性并降低护理成本。Masu。准确诊断疾病需要多年的医学教育和大量的时间。人工智慧在医疗诊断中的应用已经证明能够提供准确的诊断、支持临床判断、提高医疗保健专业人员的判断力。
电子健康记录(EHR)、医学影像资料和基因组资料等大量资料的现成可用,使得开发和检验人工智慧模型成为可能。此外,医疗保健资料的数位化和可互操作系统的引入使得收集和使用这些资料变得更加容易,使人工智慧演算法能够从不同的患者群体中学习并提高诊断准确性。我是。
医疗保健公司面临的主要障碍是资金筹措,特别是在开发中国家,很难将 IT 资金优先于医疗设备。影像设备的高成本以及人工智慧软体的实施和许可成本是限制市场成长的主要问题,特别是在医疗报销条件较差的国家。然而,开发中国家的大多数医疗机构无力实施人工智慧解决方案,例如由于安装和维护成本高昂。这一要素阻碍了创新和尖端系统的引入。
由于行业数位化和资讯系统的引入,巨量资料(庞大而复杂的资料)在医疗保健提供过程的各个阶段产生。医疗诊断领域的巨量资料包括点击流、网路和社交媒体互动产生的资讯、感测器、心电图、X射线等医疗设备的读数以及其他申请记录、生物识别资料等。包括。此外,近年来,巨量资料和分析解决方案变得更加复杂和广泛使用,医疗保健相关人员越来越接受电子病历、数位化检查幻灯片和高解析度放射影像。
深度学习模型,尤其是人工智慧演算法中使用的模型,可能很复杂且难以理解。医护人员可能会发现很难信任和理解人工智慧产生的诊断背后的逻辑,因为目前尚不清楚人工智慧如何得出结论。然而,为了让人工智慧模型被医疗保健专业人员接受和认可,它们必须易于存取和检测。
COVID-19 的疫情对全球医疗保健产业产生了负面影响。 COVID-19 感染率急剧上升,对全球卫生系统带来巨大压力。 COVID-19 患者通常会出现肺部问题。因此,乳房摄影筛检已成为确定COVID-19患者严重程度的标准诊断程序。 2020 年,使用 AI 诊断 COVID-19 的研究迅速增加。
诊断领域对基于人工智慧的软体及时提供准确诊断的需求不断增加,新的人工智慧演算法快速开发并核准新软体,放射科、循环系统、神经科、妇科、眼科等软体领域占据最大份额预测期内由于基于人工智慧的软体在各领域的应用。儘管面临人员短缺和影像扫描量增加的挑战,软体解决方案也为医疗保健提供者提供了相对于竞争对手的竞争优势。
由于实施基于人工智慧的解决方案可实现自动化诊断和减少医院负担的要素、接受诊断程序的患者数量不断增加、对疾病早期发现的需求不断增长以及专业专家的短缺等因素,医院部门预计在整个预测期内见证盈利成长。此外,医院对用于诊断的基于人工智慧的医疗技术的需求日益增长,以减少复杂性和错误,节省金钱和时间,并由专业人员和技术纯熟劳工快速轻鬆地执行。许多医院正在与数位公司合作,为患者提供云端基础的人工智慧服务和解决方案。透过在日常业务中利用这些解决方案,医院可以提高生产力和效率。
由于各种慢性病和感染疾病的罹患率不断上升、主要在中国和印度的人工智慧新兴企业数量不断增加,以及人工智慧填补人工智慧领域空白的巨大潜力,亚太地区将在预测期内持续成长。该地区的医疗基础设施预计将占据最大的市场份额。此外,股权投资和新兴企业的孵化也影响着区域市场的发展。该地区人口高龄化的加剧以及急性和慢性疾病患病的增加预计将支持该地区的市场扩张。
由于对准确、快速诊断的需求不断增加以及世界高龄化导致慢性病发病率上升等要素,亚太地区有望盈利成长。其他好处包括帮助放射科医生解读医学影像以做出快速准确的诊断、减少医学影像中的杂讯以及以较低剂量的辐射生成高品质影像。例如,
According to Stratistics MRC, the Global Artificial Intelligence (AI) in Medical Diagnostics Market is accounted for $1.3 billion in 2023 and is expected to reach $10.5 billion by 2030 growing at a CAGR of 34.2% during the forecast period. By supporting healthcare professionals in making accurate and timely treatment decisions for their patients, artificial intelligence (AI) in medical diagnostics has the potential to improve access to and the cost of healthcare. It takes years of medical education and a lot of time to diagnose a condition accurately. The application of AI to medical diagnosis has demonstrated its ability to provide precise diagnoses, support clinical decisions, and improve healthcare professionals judgment.
According to the data by the World Bank, USD 1,111.082 was spent per capita on healthcare in 2018.
Electronic health records (EHRs), medical imaging data, and genomic data, which have become readily available in huge amounts, have made it possible to develop and validate AI models. Moreover, the collection and use of these data have been made easier by the digitization of healthcare data and the deployment of interoperable systems, enabling AI algorithms to learn from a variety of patient groups and increase diagnostic precision.
The main obstacle facing healthcare companies is funding, particularly in developing nations where it is difficult to prioritize IT funds over medical equipment. Particularly in nations where the reimbursement situation is unfavorable, the high cost of imaging equipment and the implementation and licensing expenses of AI software are the main issues limiting market growth. However, due to high installation and maintenance costs, for instance, the majority of healthcare facilities in developing nations cannot afford AI solutions. The adoption of innovative or cutting-edge systems is being hampered by this factor.
Big data (huge and complex data) is produced at various phases of the care delivery process as a result of the industry's growing digitization and adoption of information systems. Big data in the field of medical diagnostics includes, among other things, information generated from clickstream and web and social media interactions, readings from medical devices like sensors, ECGs, X-rays, and other billing records, as well as biometric data. Additionally, with the increasing acceptance of EHRs, digitized laboratory slides, and high-resolution radiological images among medical professionals over the past few years, big data and analytical solutions have become exponentially more advanced and widely used.
Deep learning models in particular, which are used in AI algorithms, can be complex and challenging to understand. Healthcare practitioners might discover it difficult to trust and comprehend the logic behind AI-generated diagnoses due to the ambiguity of how AI comes to its conclusions. However, AI models must be accessible and measurable in order to be accepted and recognized by healthcare professionals.
The COVID-19 pandemic epidemic had a negative impact on the worldwide healthcare industry. The COVID-19 infection rate increased dramatically, placing an enormous burden on the global health system. Patients with COVID-19 typically experience lung problems. Therefore, to determine the severity of the disease in COVID-19 instances, cardiothoracic imaging is a standard diagnostic procedure. In 2020, the number of studies utilizing AI to diagnose COVID-19 rapidly increased.
Due to the rising demand for AI-based software in diagnostics to provide an accurate diagnosis in a timely manner, the rapid development of new AI algorithms and new software approvals, and the applications of AI-based software in a variety of fields, including radiology, cardiology, neurology, gynecology, and ophthalmology, among others, the software segment held the largest share over the projection period. Additionally, despite the challenges of having a shortage of employees and the need to deal with rising imaging scan volumes, software solutions give healthcare providers a competitive edge over their rivals.
Due to factors like the benefits of implementing AI-based solutions to automate diagnosis and reduce workload in hospitals, the rise in the number of patients undergoing diagnostic procedures, the expanding demand for early disease detection, and the shortage of medical specialists, the hospital segment is predicted to experience profitable growth throughout the forecast period. Furthermore, there is a growing need for AI-based medical technologies in hospitals that are used for diagnosis in order to reduce complexity and errors, save money and time, and be performed quickly and easily by professionals and skilled workers. Many hospitals have partnerships with digital firms to offer cloud-based AI services and solutions to their patients. By using these solutions in their daily operations, the hospitals will increase their productivity and efficiency.
Owing to the rising incidence of various chronic and infectious diseases, the rising number of AI-based startups, particularly in China and India, and the enormous potential of AI in filling the gap in the region's healthcare infrastructure, Asia Pacific is predicted to hold the largest share over the extrapolated period. Moreover, the availability of equity investments and start-up incubation has an impact on the development of regional markets. The region's rising aging population and higher prevalence of acute and chronic illnesses are both expected to boost market expansion in the region.
Due to factors including the increasing demand for accurate and prompt diagnosis and the rising frequency of chronic diseases owing to the aging population worldwide, Asia-Pacific is expected to have profitable growth. Additionally, the benefits offered by AI-based solutions in the diagnosis of different neurological diseases, such as helping radiologists interpret medical images to make a rapid and precise diagnosis, reducing noise in medical images, and producing high-quality images from lower doses of radiation, are enhancing regional growth.
Some of the key players in Artificial Intelligence (AI) in Medical Diagnostics market include: Orthofix Medical Inc., NuVasive, Inc., Baxter International Inc, OrthoPediatrics Corp., Arthrex, Inc, AlloSource, Wright Medical Group N.V., Stryker Corporation, GreenBone Ortho, Zimmer Biomet Holdings, Inc, Smith & Nephew Plc, GRAFTYS, Medtronic Plc, Bioventus Inc, Musculoskeletal Transplant Foundation, SeaSpine, GreenBone Ortho.
In September 2023, IBM commits to train 2 million in artificial intelligence in three years, with a Focus on Underrepresented Communities. To achieve this goal at a global scale, IBM is expanding AI education collaborations with universities globally, collaborating with partners to deliver AI training to adult learners, and launching new generative AI coursework through IBM SkillsBuild. This will expand upon IBM's existing programs and career-building platforms to offer enhanced access to AI education and in-demand technical roles.
In September 2023, IBM is offering a robust FSMA 204 traceability and compliance management solution capable of supporting the needs of the industry's largest enterprises and suppliers of all sizes. The solution combines the scalability and interoperability of the IBM Sterling Supply Chain Intelligence Suite and the IBM Food Trust Network with iFoodDS' traceability applications and innovative food industry, regulatory, and technical expertise.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.